Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report

Abstract

Until recently endometrial cancer has classically been divided into two categories, type 1 estrogen-dependent and predominantly endometrioid and type 2 estrogen-independent and predominantly serous, according to etiological and morphological factors. The advent of molecular oncology has led to a new classification based on cancer mutational features centered on the analysis of p53, POLE and the microsatellite status. These new findings have provided the rationale for endometrial cancer to benefit from immunotherapy as well. Here, we describe the case of a patient with advanced recurrent endometrial cancer and microsatellite instability who obtained a durable complete remission with Pembrolizumab even if she developed immune-related interstitial pneumonitis. Therefore, due to its remarkable efficacy, immunotherapy is a reasonable therapeutic option for pretreated endometrial cancer patients; nonetheless,careful surveillance during therapy is necessary for the risk of developing severe immune-related adverse events.

Keywords

• Endometrial cancer
• Immunotherapy
• Pembrolizumab
• Immune-related adverse events
• Case report